Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 2b study of selinexor-based regimens in relapsed/refractory multiple myeloma
MOH_2020-05-11_008922Phase 3Recruiting
- Sponsor
- Karyopharm Therapeutics Inc.
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of selinexor in multiple myeloma (MM) (5 arms), sponsored by Karyopharm Therapeutics Inc. Primary endpoint: Primary efficacy across all five arms. Started Mar 2020; status: recruiting.
02
Drugs
selinexor
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on MOH_2020-05-11_008922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-05-11_008922.